TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03671057
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: current practice in Jessa
Study: NCT01726088
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
Study: NCT03697850
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab after adjuvant radio-chemotherapy for the treatment of patients with muscle-invasive bladder cancer not eligible for radical cystectomy
Study: NCT01395433
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 10 mg, single dose
Study: NCT05041985
Drug: Diazepam Tablets
Normalized name: Diazepam Tablets
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diazepam 5 mg tablet once per day (bedtime) for 7 days
Study: NCT03838744
Drug: Standard arm: Trabectedin in monotherapy
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin in monotherapy
Study: NCT03838744
Drug: Experimental arm: Trabectedin + Olaparib
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin given in combination to olaparib
Study: NCT01395433
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 20 mg, single dose
Study: NCT00754884
Drug: salmon calcitonin
Normalized name: Salmon calcitonin
DrugBank: Salmon calcitonin (DB00017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
Study: NCT00099255
Drug: SGN-30
Normalized name: SGN-30
DrugBank: SGN-30 (DB05471)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03720366
Drug: enasidenib
Normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: enasidenib
Study: NCT01981447
Drug: IV Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
Study: NCT01394523
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% or 0.5%
Study: NCT01820481
Drug: WIN-901X dose level 1
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg Bid, PO, 12weeks
Study: NCT01820481
Drug: WIN-901X dose level 2
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg Bid, PO, 12weeks
Study: NCT03720366
Drug: Arm 1 probes
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: caffeine, dextromethorphan, flurbiprofen, midazolam, and omeprazole
Study: NCT01820481
Drug: WIN-901X dose level 3
Normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300mg Bid, PO, 12weeks
Study: NCT03720366
Drug: Arm 2 Probes
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: digoxin and rosuvastatin
Study: NCT03720366
Drug: Arm 3 probes
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pioglitazone
Study: NCT01248325
Drug: Saline Solution (NaCl 0,9%)
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
Study: NCT00379626
Drug: cognitive and hormone treatment
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cognitive and hormone (Leuprorelin) treatment
Study: NCT02946801
Drug: Essential oils without alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02946801
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02274610
Drug: Docetaxel-PNP
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel Polymeric Nanoparticle Formulation
Study: NCT02274610
Drug: Taxotere
Normalized name: Taxotere
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel
Study: NCT04962386
Drug: Hormone replacement therapy
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HRT women were treated with an estrogen-progesterone combination therapy packaged with estradiol tablets/estradiol and dynamic progesterone (Abbott Health Products BV, Weesp, the Netherlands).Take this medicine once a day.A course of treatment was defined as 28 days of continuous treatment.One white tablet containing 1mg of estradiol was taken daily for the first 14 days and one gray tablet containing 1mg of estradiol and 10 mg of dynamic progesterone was taken daily for the remaining 14 days.
Study: NCT03501966
Drug: Acetazolamide
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical therapy including diet
Study: NCT01128972
Drug: Sodium fluoride
Normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test fluoride toothpaste and test fluoride mouth rinse
Study: NCT01128972
Drug: Sodium monoflurophosphate
Normalized name: Sodium Monofluorophosphate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: United Kingdom marketed fluoride toothpaste
Study: NCT01128972
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water rinse
Study: NCT00147602
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01284621
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium dose, oral administration
Study: NCT01284621
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medium dose oral administration on day 2-5
Study: NCT01284621
Drug: BI 10773
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: medium dose oral administration
Study: NCT01284621
Drug: Ramipril
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low dose oral administration on day 1
Study: NCT02906566
Drug: Retinol
Normalized name: Retinol
DrugBank: Vitamin A (DB00162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Retinol in the form of vitamin A lotion
Study: NCT02796755
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.
Study: NCT04297462
Drug: Oseltamivir 3 days
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-inferiority study of 3 versus 7-days duration of PEP
Study: NCT04297462
Drug: Oseltamivir 7 days
DrugBank: Oseltamivir (DB00198)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active comparator
Study: NCT00947284
Drug: nalbuphine plus naloxone
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose administered intravenously
Study: NCT04083417
Drug: Phenoxymethylpenicillin
Normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet PcV 1000 mg x 3 for 10 days
Study: NCT04401774
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab will be given every 4 weeks at 480mg flat dose intravenously for one year (total of 13 nivolumab doses).
Study: NCT01510574
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 x 200mcg tablets of oral misoprostol
Study: NCT00626080
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
Study: NCT00158678
Drug: concomitant cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 D1, D22, D43
Study: NCT01441960
Drug: Succinylcholine
Normalized name: Succinylcholine
DrugBank: Succinylcholine (DB00202)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
Study: NCT01441960
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
Study: NCT01737866
Drug: AMG 423
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: omecamtiv mecarbil
Study: NCT02408744
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
Study: NCT03235050
Drug: MEDI0382 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT03235050
Drug: MEDI0382 high dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT04219982
Drug: DPI-386 Nasal Gel
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nasal gel
Study: NCT03235050
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT00245206
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
Study: NCT00245206
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
Study: NCT00089492
Drug: enfuvirtide [Fuzeon]
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180mg sc once daily for 48 weeks
Study: NCT00089492
Drug: enfuvirtide [Fuzeon]
DrugBank: Enfuvirtide (DB00109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90mg sc bid for 48 weeks
Study: NCT00245206
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
Study: NCT04187560
Drug: LB-102
Normalized name: LB-102
DrugBank: LB-102 (DB19214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (N-Methyl amisulpride)
Study: NCT03137498
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
Study: NCT01306656
Drug: 10,000 IU Vitamin D3
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Month 1: 20,000 IU vitamin D3 once a week~Months 2-6: 10,000 IU vitamin D3 once a week
Study: NCT00592332
Drug: Alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
Study: NCT02319135
Drug: Azacitadine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02319135
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02319135
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02319135
Drug: Lenograstim
Normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02319135
Drug: Filgastrim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03354624
Drug: Sterile solutions of recombinant human nerve growth factor (NGF)
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intramuscular injections of NGF cause muscle soreness.
Study: NCT02286635
Drug: Deflazacort and rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
Study: NCT04267081
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ex vivo venetoclax sensitivity testing is used for patient selection.
Study: NCT00133224
Drug: Chemotherapy (docetaxel and prednisone)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (docetaxel and prednisone)
Study: NCT02408523
Drug: Lacosamide Tablet
Normalized name: Lacosamide Tablets
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study: NCT00020696
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00020696
Drug: tirapazamine
Normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00775931
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients\<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
Study: NCT00775931
Drug: Fludarabine monophosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
Study: NCT01988831
Drug: Propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This intervention apply to Propranolol group
Study: NCT02408523
Drug: Lasosamide Oral Solution
Normalized name: lacosamide Oral Tablet
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Oral Solution~* Concentration: 10 mg/ml~* Route of Administration: Oral use
Study: NCT02287558
Drug: Pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00947284
Drug: nalbuphine plus saline
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose administered intravenously
Study: NCT00519818
Drug: Cortef
Normalized name: Cortef
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
Study: NCT00590447
Drug: rituximab monotherapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
Study: NCT03573947
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 360 mg intravenously every 3 weeks
Study: NCT03573947
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg/kg intravenously over 30 minutes
Study: NCT03573947
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m2 on days 1 and 8 of every 21-day treatment cycle
Study: NCT00874523
Drug: atazanavir plus raltegravir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
Study: NCT00874523
Drug: atazanavir plus raltegravir
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
Study: NCT00947284
Drug: naloxone plus saline
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose administered intravenously
Study: NCT01561833
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
Study: NCT01854684
Drug: Temoporfin
Normalized name: Temoporfin
DrugBank: Temoporfin (DB11630)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02972554
Drug: Propanolol hydrochloride
Normalized name: Propanolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One-time dose of 40mg of propranolol
Study: NCT00885755
Drug: trastuzumab [Herceptin]
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
Study: NCT01603654
Drug: sodium picosulphate magnesium citrate
Normalized name: Sodium Picosulfate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
Study: NCT01135472
Drug: Esomeprazole Magnesium
Normalized name: Esomeprazole Magnesium
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
Study: NCT00328172
Drug: BI 1356 dose 3 once daily
Normalized name: 1,4-bis(3-bromopropionyl)piperazine
DrugBank: Pipobroman (DB00236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BI 1356 dose 3 once daily
Study: NCT00328172
Drug: BI 1356 dose 2 once daily
Normalized name: Bis(2-benzothiazolyl) disulfide
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BI 1356 dose 2 once daily
Study: NCT00328172
Drug: BI 1356 dose 1 once daily
Normalized name: Bis(1-piperidylthiocarbonyl) disulfide
DrugBank: Disulfiram (DB00822)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BI 1356 dose 1 once daily
Study: NCT00328172
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin
Study: NCT01343888
Drug: BI 201335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 201335 once daily high dose
Study: NCT01343888
Drug: BI 201335
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 201335 once daily low dose
Study: NCT01677260
Drug: 500 mg metformin hydrochloride extended release caplet (test drug)
Normalized name: metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
Study: NCT01677260
Drug: 500 mg metformin hydrochloride prolonged release tablet (reference drug)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
Study: NCT02795039
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
Study: NCT02795039
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)